As emphasized by Sonkin et al., the field’s progression toward multi-target combinations (e.g., kinase inhibitor cocktails in cancer) and pathway-centric pharmacology (e.g., PI3K-Akt axis modulation) has redefined therapeutic design for complex diseases [4]. The gene discussed is AKT1; the disease is cancer.